Literature DB >> 28695084

Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.

S L Suryawanshi1, H D Shewade2, S B Nagaraja3, S A Nair1, M Parmar1.   

Abstract

Setting: Patients with multidrug-resistant tuberculosis (MDR-TB) registered for treatment (2011-2012 cohort) using the standard 24-month regimen, under the Revised National TB Control Programme's programmatic management of drug-resistant TB (PMDT), Maharashtra, India.
Objectives: To assess the treatment outcomes and the timing and risk factors for unfavourable treatment outcomes, with a focus on death and loss to follow-up (LTFU). Method: This was a retrospective cohort study involving a review of PMDT records. Treatment outcomes were reported on 31 December 2014.
Results: Of 4024 patients, treatment success was recorded in 1168 (29%). Unfavourable outcomes occurred in 2242 (56%), of whom 857 (21%) died and 768 (19%) were lost to follow-up. Treatment outcomes were missing on record review for 375 (9%) patients, and 239 (6%) were still undergoing treatment. Half of LTFU occurred within 3 months, and more than four fifths of deaths occurred after 6 months of treatment. Human immunodeficiency virus infection, being underweight, age ⩾ 15 years, male sex and pulmonary TB were the main risk factors for death, LTFU or other unfavourable treatment outcomes.
Conclusion: The study found poor treatment outcomes in patients with MDR-TB registered for treatment in Maharashtra, India. Interventions are required to address the high rates of LTFU and death.

Entities:  

Keywords:  India; death; loss to follow-up; multidrug-resistant tuberculosis; operational research

Year:  2017        PMID: 28695084      PMCID: PMC5493092          DOI: 10.5588/pha.17.0013

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  11 in total

1.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

Authors:  Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

2.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

3.  High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.

Authors:  C Kuaban; J Noeske; H L Rieder; N Aït-Khaled; J L Abena Foe; A Trébucq
Journal:  Int J Tuberc Lung Dis       Date:  2015-05       Impact factor: 2.373

4.  Impact of rapid molecular diagnostic tests on time to treatment initiation and outcomes in patients with multidrug-resistant tuberculosis, Tamil Nadu, India.

Authors:  Dina Nair; Pooranaganga D Navneethapandian; Jaya Prasad Tripathy; Anthony D Harries; Joel S Klinton; Basilea Watson; Gomathi N Sivaramakrishnan; Devarajulu S Reddy; Lakshmi Murali; Mohan Natrajan; Soumya Swaminathan
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-10-13       Impact factor: 2.184

5.  Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children.

Authors:  R M Hicks; N Padayatchi; N S Shah; A Wolf; L Werner; V B Sunkari; M R O'Donnell
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

6.  High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.

Authors:  A Piubello; S Hassane Harouna; M B Souleymane; I Boukary; S Morou; M Daouda; Y Hanki; A Van Deun
Journal:  Int J Tuberc Lung Dis       Date:  2014-10       Impact factor: 2.373

7.  Drug-resistant tuberculosis in Mumbai, India: An agenda for operations research.

Authors:  Nerges Mistry; Monica Tolani; David Osrin
Journal:  Oper Res Health Care       Date:  2012-06

8.  Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.

Authors:  Teye Umanah; Jabulani Ncayiyana; Xavier Padanilam; Peter S Nyasulu
Journal:  BMC Infect Dis       Date:  2015-10-28       Impact factor: 3.090

9.  Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India.

Authors:  Petros Isaakidis; Roma Paryani; Samsuddin Khan; Homa Mansoor; Mamta Manglani; Asmaa Valiyakath; Peter Saranchuk; Jennifer Furin
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

10.  Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.

Authors:  Daniel Meressa; Rocío M Hurtado; Jason R Andrews; Ermias Diro; Kassim Abato; Tewodros Daniel; Paritosh Prasad; Rebekah Prasad; Bekele Fekade; Yared Tedla; Hanan Yusuf; Melaku Tadesse; Dawit Tefera; Abraham Ashenafi; Girma Desta; Getachew Aderaye; Kristian Olson; Sok Thim; Anne E Goldfeld
Journal:  Thorax       Date:  2015-10-27       Impact factor: 9.139

View more
  10 in total

1.  Development and Validation of a Nomogram for the Prediction of Unfavorable Treatment Outcome Among Multi-Drug Resistant Tuberculosis Patients in North West Ethiopia: An Application of Prediction Modelling.

Authors:  Denekew Tenaw Anley; Temesgen Yihunie Akalu; Mehari Woldemariam Merid; Tewodros Tsegaye
Journal:  Infect Drug Resist       Date:  2022-07-21       Impact factor: 4.177

2.  Patients with MDR-TB on domiciliary care in programmatic settings in Myanmar: Effect of a support package on preventing early deaths.

Authors:  Pyae Phyo Wai; Hemant Deepak Shewade; Nang Thu Thu Kyaw; Khine Wut Yee Kyaw; Saw Thein; Aung Si Thu; Myo Minn Oo; Pyae Sone Htwe; Moe Myint Theingi Tun; Htet Myet Win Maung; Kyaw Thu Soe; Si Thu Aung
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

3.  Use of Verbal Autopsy to Determine Underlying Cause of Death during Treatment of Multidrug-Resistant Tuberculosis, India.

Authors:  Poonam Ramesh Naik; Patrick K Moonan; Abhay Subhashrao Nirgude; Hemant Deepak Shewade; Srinath Satyanarayana; Pracheth Raghuveer; Malik Parmar; Chinnappareddy Ravichandra; Anil Singarajipura
Journal:  Emerg Infect Dis       Date:  2018-03       Impact factor: 6.883

4.  Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.

Authors:  Gina Gualano; Paola Mencarini; Maria Musso; Silvia Mosti; Laura Santangelo; Silvia Murachelli; Angela Cannas; Antonino Di Caro; Assunta Navarra; Delia Goletti; Enrico Girardi; Fabrizio Palmieri
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

5.  Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience.

Authors:  Abhijeet Singh; Rajendra Prasad; Ram Awadh Singh Kushwaha; Rahul Srivastava; Belur Hosmane Giridhar; Viswesvaran Balasubramanian; Amita Jain
Journal:  Lung India       Date:  2019 Sep-Oct

6.  "Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.

Authors:  Arjunkumar Jakasania; Kalpita Shringarpure; Dixit Kapadia; Radhika Sharma; Kedar Mehta; Arpit Prajapati; Soundappan Kathirvel
Journal:  BMC Infect Dis       Date:  2020-12-02       Impact factor: 3.090

7.  Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies.

Authors:  Dumessa Edessa; Fuad Adem; Bisrat Hagos; Mekonnen Sisay
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240

8.  Operational research within a Global Fund supported tuberculosis project in India: why, how and its contribution towards change in policy and practice.

Authors:  Karuna D Sagili; Srinath Satyanarayana; Sarabjit S Chadha; Nevin C Wilson; Ajay M V Kumar; Patrick K Moonan; John E Oeltmann; Vineet K Chadha; Sharath Burugina Nagaraja; Smita Ghosh; Terrence Q Lo; Tyson Volkmann; Matthew Willis; Kalpita Shringarpure; Ravichandra Chinnappa Reddy; Prahlad Kumar; Sreenivas A Nair; Raghuram Rao; Mohammed Yassin; Perry Mwangala; Rony Zachariah; Jamhoih Tonsing; Anthony D Harries; Sunil Khaparde
Journal:  Glob Health Action       Date:  2018       Impact factor: 2.640

9.  Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013.

Authors:  M Verdecchia; K Keus; S Blankley; D Vambe; C Ssonko; T Piening; E C Casas
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

10.  Extrapulmonary drug-resistant tuberculosis at a drug-resistant tuberculosis center, Mumbai: Our experience - Hope in the midst of despair!

Authors:  Unnati Desai; Jyotsna M Joshi
Journal:  Lung India       Date:  2019 Jan-Feb
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.